$3.83
+1.86%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$3.87
From 52W high−91.85%
Volume8174.00
Market cap$6.25M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$3.87
From 52W high
−91.85%
Volume
8174.00
Market cap
$6.25M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
P/E (TTM)
—
RSI (14)
38.4
MomentumView details →
1D Return
+1.86%
YTD Return
−87.20%
SummaryUpdated Jun 1, 2026
Eterna Therapeutics Inc. (NASDAQ:ERNA), formerly known as Brooklyn ImmunoTherapeutics, is a clinical-stage biopharmaceutical company founded in 1991 and based in Brooklyn, New York. The company focuses on developing innovative cancer treatments through immunotherapy and advanced gene-editing technologies. As a biotechnology firm in the oncology space, Eterna operates in the high-risk, high-reward pharmaceutical development sector where companies invest years and substantial capital to bring potentially life-saving treatments from laboratory research through clinical trials to market approval.
Similar companies
Latest newsMore news →
Ernexa Therapeutics Inc. appointed Robert J. Spiegel, M.D. to its Board of Directors effective September 14, 2026.4d agoErnexa Therapeutics reported positive preclinical disease-modifying data for ERNA-201 in the collagen-induced arthritis model, supporting its engineered synthetic iMSC platform.5d ago